Consano Bio | Science

C-1101

C-1101 is Consano Bio’s lead investigational therapy designed to treat chronic painful lumbosacral radiculopathy (LSR), or chronic sciatica.

C-1101 is a purified, multi-protein solution derived from human platelets in plasma collected from healthy donors. The product contains consistent concentrations of cytokines, growth factors, and matrix proteins to help trigger the body’s natural healing response.

Delivered via an epidural injection, C-1101 provides supraphysiologic concentrations of these proteins directly to the site of nerve injury. Through this targeted delivery, C-1101 is intended to:

Modulate inflammation and promote reparative inflammation.
Promote cellular proliferation and repair through platelet-derived growth factors.

Preclinical Research

Preclinical studies have demonstrated inflammatory modulation, local cell proliferation and neuronal repair, supporting the potential for disease modification.

Inflammation Modulation

Reduced LPS-induced cytokine production in vitro in human macrophage cells in a dose-responsive manner

Neuropathic Pain

Reduced paclitaxel-induced cool allodynia (measure of neuropathic pain) in mice

Local Cell Proliferation & Tissue Remodeling

Demonstrated active growth factors in reporter cell assays
Induced dose-dependent hMSC (human Mesenchymal Stromal Cells) proliferation

C-1101 Phase 1 Trial in Chronic Painful LSR

Consano Bio is investigating C-1101 in a first-in-human Phase 1 clinical trial in patients with chronic painful LSR.

The multi-center randomized, blinded, and controlled dose-escalation study is intended to enroll 24 patients across three sequential single-dose cohorts to evaluate the safety and tolerability of C-1101 delivered via a single epidural injection.

Additional assessments include measures of pain, physical function, and sleep quality, all key indicators of clinical improvement in chronic painful LSR.

More information about the C-1101 Phase 1 clinical trial may be accessed on ClinicalTrials.gov.